PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma—a case report

[1]  L. Zhong,et al.  Malignant Craniopharyngioma: A Report of Seven Cases and Review of the Literature. , 2019, World neurosurgery.

[2]  H. Takeshima,et al.  Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas , 2018, Brain Tumor Pathology.

[3]  D. Wheeler,et al.  Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma , 2017, Journal of neuropathology and experimental neurology.

[4]  J. Brugarolas.  PBRM1 and BAP1 as novel targets for renal cell carcinoma. , 2013, Cancer journal.

[5]  C. Sander,et al.  Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.

[6]  P. Kapur,et al.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. , 2013, The Lancet. Oncology.

[7]  S. Hettige,et al.  Malignant transformation in craniopharyngiomas. , 2012, Neurosurgery.

[8]  Srinivasan Vijayakumar,et al.  Radiation induced renal cell cancer: a report of 4 cases and review of the literature. , 1999, The Journal of urology.

[9]  J. Bruner,et al.  The descriptive epidemiology of craniopharyngioma. , 1998, Neurosurgical focus.

[10]  P. Hall,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[11]  P. Sparén,et al.  Second primary cancer after treatment for cervical cancer. An international cancer registries study , 1995, Cancer.